Search Results

• • 37 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Reply to: Caution at psychiatry's psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy.

  Authors:Jennifer Mitchell, Allison Coker, and Berra Yazar-KlosinskiFrom:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20211,266 words Letter to the editor 1610LAuthor(s): Jennifer Mitchell 1 2 3 , Allison Coker 1 4 , Berra Yazar-Klosinski 5 Author Affiliations: (1) Department of Neurology, University of California, San Francisco, San Francisco, USA (2) Department of...

• Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.

  Authors:R. Dummer, D. E. Gyorki, J. Hyngstrom, A. C. Berger, R. Conry, L. Demidov, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20219,683 words Report 1420LTalimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable melanoma. The present, ongoing study aimed to estimate the...

• Hepatitis B: a new weapon against an old enemy.

  Author:T. Jake LiangFrom:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20211,402 words Report 1460LNew strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis B--a pilot clinical study of antisense oligonucleotide treatment shows the potential promise of this approach. Author(s):...

• Empowering prosthesis users with a hip exoskeleton.

  Authors:Varun Nalam and He (Helen) HuangFrom:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20211,480 words Report 1650LA phase 1 trial shows the feasibility of a novel approach combining a powered hip exoskeleton with a passive leg prosthesis to improve the energy efficiency of walking. Author(s): Varun Nalam 1 2 , He (Helen) Huang 1 2...

• Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.

  Authors:Noa Dagan, Noam Barda, Tal Biron-Shental, Maya Makov-Assif, Calanit Key, Isaac S. Kohane, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20213,938 words Report 1510LTo evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were...

• Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.

  Authors:Randolph P. Matthews, Munjal Patel, Stephanie E. Barrett, Liesbeth Haspeslagh, Tom Reynders, Saijuan Zhang, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20216,391 words Report 1570LIslatravir (MK-8591) is a highly potent type 1 human immunodeficiency virus (HIV-1) nucleoside reverse transcriptase translocation inhibitor with a long intracellular half-life that is in development for the prevention...

• Federated learning for predicting clinical outcomes in patients with COVID-19.

  Authors:Ittai Dayan, Holger R. Roth, Aoxiao Zhong, Ahmed Harouni, Amilcare Gentili, Anas Z. Abidin, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 202111,827 words Report 1540LFederated learning (FL) is a method used for training artificial intelligence models with data from multiple sources while maintaining data anonymity, thus removing many barriers to data sharing. Here we used data from...

• Challenges with benchmarking of MDMA-assisted psychotherapy.

  Authors:Joar Øveraas Halvorsen, Florian Naudet, and Ioana A. CristeaFrom:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20211,367 words Report 1620LAuthor(s): Joar Øveraas Halvorsen 1 2 , Florian Naudet 3 , Ioana A. Cristea 4 Author Affiliations: (1) Department of Psychology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (2) St....

• Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.

  Authors:Kathryn E. Stephenson, Boris Julg, C. Sabrina Tan, Rebecca Zash, Stephen R. Walsh, Charlotte-Paige Rolle, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 202112,141 words Report 1620LHuman immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind,...

• Health-based civic engagement is a professional responsibility.

  Authors:Simar Singh Bajaj, Alister Francois Martin, and Fatima Cody StanfordFrom:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20211,410 words Letter to the editor 1630LAuthor(s): Simar Singh Bajaj 1 , Alister Francois Martin 2 3 , Fatima Cody Stanford 4 5 6 7 Author Affiliations: (1) Department of the History of Science, Harvard University, Cambridge, USA (2) Department of...

• ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.

  Authors:Roberto A. Calle, Neeta B. Amin, Santos Carvajal-Gonzalez, Trenton T. Ross, Arthur Bergman, Sudeepta Aggarwal, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 202116,020 words Report 1630LAlterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for...

• Publisher Correction: Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial.

  Authors:Charlotte K. Boughton, Afroditi Tripyla, Sara Hartnell, Aideen Daly, David Herzig, Malgorzata E. Wilinska, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 2021177 words Correction notice, B... 1400LAuthor(s): Charlotte K. Boughton 1 2, Afroditi Tripyla 3, Sara Hartnell 2, Aideen Daly 1, David Herzig 3, Malgorzata E. Wilinska 1, Cecilia Czerlau 4, Andrew Fry 5, Lia Bally 3, Roman Hovorka 1 Author Affiliations:...

• Author Correction: Pan-viral serology implicates enteroviruses in acute flaccid myelitis.

  Authors:Ryan D. Schubert, Isobel A. Hawes, Prashanth S. Ramachandran, Akshaya Ramesh, Emily D. Crawford, John E. Pak, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 2021500 words Correction notice 2390LAuthor(s): Ryan D. Schubert 1 2, Isobel A. Hawes 1 2, Prashanth S. Ramachandran 1 2, Akshaya Ramesh 1 2, Emily D. Crawford 3 4, John E. Pak 3, Wesley Wu 3, Carly K. Cheung 3, Brian D. O'Donovan 5, Cristina M. Tato 3, Amy...

• Individualized therapy trials: navigating patient care, research goals and ethics.

  Authors:Patrick Bodilly Kane, Merlin Bittlinger, and Jonathan KimmelmanFrom:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20217,664 words Report 1500L'Individualized therapy' trials (sometimes called n-of-1 trials) use patients as their own controls to evaluate treatments. Here we divide such trials into three categories: multi-crossover trials aimed at individual...

• Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.

  Authors:Gretchen Thomsen, Arthur H. M. Burghes, Caroline Hsieh, Janet Do, Binh T. T. Chu, Stephanie Perry, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20218,267 words Report 1590LSpinal muscular atrophy type 1 (SMA1) is a debilitating neurodegenerative disease resulting from survival motor neuron 1 gene (SMN1) deletion/mutation. Onasemnogene abeparvovec (formerly AVXS-101) is a gene therapy that...

• A quality assessment tool for artificial intelligence-centered diagnostic test accuracy studies: QUADAS-AI.

  Authors:Viknesh Sounderajah, Hutan Ashrafian, Sherri Rose, Nigam H. Shah, Marzyeh Ghassemi, Robert Golub, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20211,929 words Letter to the editor 1770LAuthor(s): Viknesh Sounderajah 1 2 , Hutan Ashrafian 1 2 , Sherri Rose 3 , Nigam H. Shah 4 , Marzyeh Ghassemi 5 , Robert Golub 6 , Charles E. Kahn Jr 7 , Andre Esteva 8 , Alan Karthikesalingam 9 , Bilal Mateen 10 , Dale...

• Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.

  Authors:Evdoxia Kyriazopoulou, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Konstantinos Tsiakos, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20218,910 words Report 1390LEarly increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE...

• COVID-19 vaccination gives hope to eradicate polio.

  Authors:Mohammad Ali, Jafar Khan, Nisar Ahmad, Haji Khan, Arshad Iqbal, Muhammad Rizwan, et al.From:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 2021868 words Letter to the editor 1560LAuthor(s): Mohammad Ali 1 , Jafar Khan 1 , Nisar Ahmad 1 , Haji Khan 1 , Arshad Iqbal 1 , Muhammad Rizwan 1 , Murad Ali 1 , Bilal Haider Abbasi 2 Author Affiliations: (1) Centre for Biotechnology and Microbiology,...

• Calming the cytokine storm in COVID-19.

  Authors:Randy Q. Cron, Roberto Caricchio, and W. Winn ChathamFrom:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20211,195 words Report 1530LCytokine blockade can improve the survival rate of patients with COVID-19 who are at risk of respiratory failure, but timing and patient selection are key. Author(s): Randy Q. Cron 1 , Roberto Caricchio 2 , W. Winn...

• Powered hip exoskeleton improves walking economy in individuals with above-knee amputation.

  Authors:Marshall K. Ishmael, Dante Archangeli, and Tommaso LenziFrom:Nature Medicine (Vol. 27, Issue 10) Peer-Reviewed

  Oct. 20217,335 words Report 1470LAbove-knee amputation severely reduces the mobility and quality of life of millions of individuals. Walking with available leg prostheses is highly inefficient, and poor walking economy is a major problem limiting...